Widely used:Recently Viewed
Clear AllToday’s Range
52 Week Range
Liquidity
Market cap
$200 Mln
Revenue (TTM)
$0 Mln
Net Profit (TTM)
$0 Mln
ROE
0 %
ROCE
-- %
P/E Ratio
--
P/B Ratio
0
Industry P/E
--
EV/EBITDA
0
Div. Yield
0 %
Debt to Equity
0
Book Value
$--
EPS
$--
Face value
--
Shares outstanding
31,000,000
CFO
$--
EBITDA
$--
Net Profit
$--
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
JUPITER NEUROSCIENCES INC (JUNS)
| -94.7 | -9.2 | -32.8 | -- | -- | -- | -- |
|
BSE Sensex*
| 4.5 | 4.1 | 7.7 | 10.5 | 15.7 | 22.0 | 11.5 |
|
S&P Small-Cap 600#
| -5.8 | -5.3 | -13.7 | -6.3 | 5.3 | 3.0 | 5.5 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Company |
Price ($) | Market Cap ($ Mln) | Revenue (TTM) | Net Profit (TTM) | OPM (%) | ROE (%) | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
|
JUPITER NEUROSCIENCES INC (JUNS)
|
0.6 | 200.2 | 0.0 | -3.3 | -- | -- | -- | 0.0 |
| 2.3 | 3.6 | 0.7 | -10.3 | -1,278.2 | -203.6 | -- | 0.0 | |
| 0.3 | 4.1 | 7.5 | -9.0 | -144,731.8 | -0.3 | -- | 0.7 | |
| 0.7 | 162.9 | 1.0 | -155.9 | -15,251.5 | -- | -- | 0.0 | |
| 7.9 | 207.6 | 7.0 | -20.0 | -271.4 | -13.4 | -- | 1.4 | |
| 2.3 | 16.2 | 2.9 | -8.4 | -181.0 | -- | -- | 63.9 | |
| 1.3 | 208.8 | 41.6 | -202.0 | -496.2 | -136.3 | -- | 2.0 | |
| 0.5 | 16.8 | 0.0 | -0.9 | -- | -11.2 | 5.7 | 1.8 | |
| 196.8 | 12,755.3 | 16,084.1 | 1,196.9 | 10.9 | 17.4 | 11.1 | 1.9 | |
| 0.9 | 4.1 | 0.0 | -3.3 | -- | -109.8 | -- | 1.2 |
Jupiter Neurosciences, Inc., a clinical stage research and development pharmaceutical company, develops resveratrol platform products for the treatment of neuroinflammation. The company develops JNS101, which is in Phase II trial for the treatment of... Friedreich's Ataxia, a rare inherited disease that causes damage to the nervous system, as well as mobility dysfunctions; and JNS108 that is in Phase II trial for treating mild cognitive impairment/early Alzheimer's disease. It is also involved in the development of JNS102, which is in Phase II trial for the treatment of mucopolysaccharidosis type 1; and JNS107 that is in Phase II trial for treating mitochondrial encephalopathy, lactic acidosis, and stroke-like episodes syndrome. In addition, the company develops JNS115, which is in Phase IIa trial for the treatment of Parkinson's disease. It has a strategic partnership with Zina Biopharmaceuticals, LLC to advance Phase 2a clinical trial to evaluate the safety, tolerability, and pharmacokinetics of Resveratrol (JOTROLTM) in individuals with Parkinson's disease; and with Aquanova AG to develop a series of consumer-focused nutritional products targeting longevity, aging, and healthspan. The company was formerly known as Jupiter Orphan Therapeutics, Inc. and changed its name to Jupiter Neurosciences, Inc. in August 2021. Jupiter Neurosciences, Inc. was incorporated in 2016 and is headquartered in Jupiter, Florida. Read more
Co-Founder, CEO & Chairman of the Board
Mr. Christer Rosen
Co-Founder, CEO & Chairman of the Board
Mr. Christer Rosen
Headquarters
Jupiter, FL
Website
Our rating system has guided millions of investors in the past 20 years.
The total asset value of JUPITER NEUROSCIENCES INC (JUNS) stood at $ 9 Mln as on 31-Mar-25
The share price of JUPITER NEUROSCIENCES INC (JUNS) is $0.56 (NASDAQ) as of 19-May-2025 16:00 EDT. JUPITER NEUROSCIENCES INC (JUNS) has given a return of --% in the last 1 years.
JUPITER NEUROSCIENCES INC (JUNS) has a market capitalisation of $ 200 Mln as on 16-May-2025. As per Value Research classification, it is a Small Cap company.
Since, TTM earnings of JUPITER NEUROSCIENCES INC (JUNS) is negative, P/E ratio is not available.
Step 1. Open a demat account through a broker. You would need to provide your email, PAN, bank account details, aadhar details, etc., for KYC
Step 2. Sign in to the broker’s application through a mobile app or website. Use the Login ID and password provided by your broker.
Step 3. Transfer funds from your bank account into the wallet present in your brokerage account.
Step 4. Search for the JUPITER NEUROSCIENCES INC (JUNS) and enter the required number of quantities and click on buy to purchase the shares of JUPITER NEUROSCIENCES INC (JUNS).
Jupiter Neurosciences, Inc., a clinical stage research and development pharmaceutical company, develops resveratrol platform products for the treatment of neuroinflammation. The company develops JNS101, which is in Phase II trial for the treatment of Friedreich's Ataxia, a rare inherited disease that causes damage to the nervous system, as well as mobility dysfunctions; and JNS108 that is in Phase II trial for treating mild cognitive impairment/early Alzheimer's disease. It is also involved in the development of JNS102, which is in Phase II trial for the treatment of mucopolysaccharidosis type 1; and JNS107 that is in Phase II trial for treating mitochondrial encephalopathy, lactic acidosis, and stroke-like episodes syndrome. In addition, the company develops JNS115, which is in Phase IIa trial for the treatment of Parkinson's disease. It has a strategic partnership with Zina Biopharmaceuticals, LLC to advance Phase 2a clinical trial to evaluate the safety, tolerability, and pharmacokinetics of Resveratrol (JOTROLTM) in individuals with Parkinson's disease; and with Aquanova AG to develop a series of consumer-focused nutritional products targeting longevity, aging, and healthspan. The company was formerly known as Jupiter Orphan Therapeutics, Inc. and changed its name to Jupiter Neurosciences, Inc. in August 2021. Jupiter Neurosciences, Inc. was incorporated in 2016 and is headquartered in Jupiter, Florida.
The CEO & director of Mr. Christer Rosen. is JUPITER NEUROSCIENCES INC (JUNS), and CFO & Sr. VP is Mr. Christer Rosen.
There is no promoter pledging in JUPITER NEUROSCIENCES INC (JUNS).
Some of the close peers are:
| Company | Market Cap($ Mln) |
|---|---|
|
20
|
|
|
16
|
|
|
2
|
|
|
2
|
|
|
0
|
|
|
0
|
|
|
0
|
|
|
0
|
|
|
1,210
|
| JUPITER NEUROSCIENCES INC. (JUNS) | Ratios |
|---|---|
|
Return on equity(%)
|
--
|
|
Operating margin(%)
|
--
|
|
Net Margin(%)
|
--
|
|
Dividend yield(%)
|
--
|
No, TTM profit after tax of JUPITER NEUROSCIENCES INC (JUNS) was $0 Mln.
$-0.02
(
